Tag - RP-G28

By Len Zehr Ritter Pharmaceuticals’ (NASDAQ:RTTR) lead product candidate, RP-G28, which recently entered Phase 3 clinical trials, has the potential to become the first prescription therapy for lactose intolerance, a...